Lymphoma-based therapy for refractory or relapsed Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in children
Copyright © 2022 Formosan Medical Association. Published by Elsevier B.V. All rights reserved..
Epstein-Barr virus-related hemophagocytic lymphohistiocytosis (EBV-HLH) is a life-threatening hyperinflammatory syndrome. Although etoposide-based immunochemotherapy has improved survival rates, consensus regarding the appropriate salvage therapy for patients with refractory or relapsed EBV-HLH is lacking. We performed a retrospective study to examine the efficacy of a lymphoma-based treatment regimen for children with refractory or relapsed EBV-HLH. The data of six children were analyzed. Four had cytogenetic abnormalities, and two experienced a transition to EBV-positive T-cell lymphoma. They were treated with an intensive chemotherapy regimen modified from that used in the Berlin-Frankfurt-Münster Group Trial as salvage therapy. Five patients (83%) achieved complete response. Four patients (67%) were disease free for a median of 10 years without undergoing allogeneic hematopoietic stem cell transplantation. No grade 3 or 4 nonhematologic adverse events occurred. Lymphoma-based chemotherapy is a potential curative treatment for some subgroups of children with refractory or relapsed EBV-HLH.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:121 |
|---|---|
| Enthalten in: |
Journal of the Formosan Medical Association = Taiwan yi zhi - 121(2022), 11 vom: 15. Nov., Seite 2351-2355 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cheng, Chao-Neng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6PLQ3CP4P3 |
|---|
| Anmerkungen: |
Date Completed 18.10.2022 Date Revised 18.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jfma.2022.01.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336563787 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336563787 | ||
| 003 | DE-627 | ||
| 005 | 20231225232427.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jfma.2022.01.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1121.xml |
| 035 | |a (DE-627)NLM336563787 | ||
| 035 | |a (NLM)35123848 | ||
| 035 | |a (PII)S0929-6646(22)00009-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cheng, Chao-Neng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lymphoma-based therapy for refractory or relapsed Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in children |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.10.2022 | ||
| 500 | |a Date Revised 18.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Formosan Medical Association. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Epstein-Barr virus-related hemophagocytic lymphohistiocytosis (EBV-HLH) is a life-threatening hyperinflammatory syndrome. Although etoposide-based immunochemotherapy has improved survival rates, consensus regarding the appropriate salvage therapy for patients with refractory or relapsed EBV-HLH is lacking. We performed a retrospective study to examine the efficacy of a lymphoma-based treatment regimen for children with refractory or relapsed EBV-HLH. The data of six children were analyzed. Four had cytogenetic abnormalities, and two experienced a transition to EBV-positive T-cell lymphoma. They were treated with an intensive chemotherapy regimen modified from that used in the Berlin-Frankfurt-Münster Group Trial as salvage therapy. Five patients (83%) achieved complete response. Four patients (67%) were disease free for a median of 10 years without undergoing allogeneic hematopoietic stem cell transplantation. No grade 3 or 4 nonhematologic adverse events occurred. Lymphoma-based chemotherapy is a potential curative treatment for some subgroups of children with refractory or relapsed EBV-HLH | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Epstein–Barr virus | |
| 650 | 4 | |a Hemophagocytic lympho-histiocytosis | |
| 650 | 4 | |a Refractory | |
| 650 | 4 | |a Relapse | |
| 650 | 4 | |a T-cell lymphoma | |
| 650 | 7 | |a Etoposide |2 NLM | |
| 650 | 7 | |a 6PLQ3CP4P3 |2 NLM | |
| 700 | 1 | |a Chu, Wei-Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Kung-Chao |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jiann-Shiuh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the Formosan Medical Association = Taiwan yi zhi |d 1992 |g 121(2022), 11 vom: 15. Nov., Seite 2351-2355 |w (DE-627)NLM012627941 |x 0929-6646 |7 nnns |
| 773 | 1 | 8 | |g volume:121 |g year:2022 |g number:11 |g day:15 |g month:11 |g pages:2351-2355 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jfma.2022.01.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 121 |j 2022 |e 11 |b 15 |c 11 |h 2351-2355 | ||